Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look

M. B. Ojeda-González, I. Alvárez-López, M. C. Alonso-Muñoz, J. Badía-Serra, E. Delgado-Latre, L. De Andrés- Basauri, J. J. López- L Ó Pez

    Research output: Contribution to journalArticleResearchpeer-review

    1 Citation (Scopus)

    Abstract

    Seventy-two patients with advanced ovarian cancer received CAP chemotherapy followed by laparotomy and ‘second-effort’ surgery. The overall response to CAP therapy was 80%. A complete pathological response (CPR) was obtained in 16 patients and partial microscopic (PMiR) and macroscopic responses in 7 and 33 cases, respectively. The actuarial survival for the entire group was 36% at 50 months with a median survival of 34 months. No significant differences in survival between the CPR and PMiR groups were found. Radical second-effort surgery showed a somewhat beneficial effect. The tumor size before chemotherapy (<5 cm) and FIGO stage III had a significantly favorable effect on response rate and survival. © 1991 S. Karger AG, Basel.
    Original languageEnglish
    Pages (from-to)7-12
    JournalOncology (Switzerland)
    Volume48
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 1991

    Keywords

    • Adriamycin
    • Advanced ovarian cancer
    • Chemotherapy
    • Cisplatin
    • Cyclophosphamide
    • Doxorubicin
    • Laparotomy
    • Ovarian cancer, FIGO stages III and IV
    • Second-effort surgery
    • Second-look

    Fingerprint

    Dive into the research topics of 'Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look'. Together they form a unique fingerprint.

    Cite this